Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Talen Energy Corp V.TLN


Primary Symbol: TLN

Talen Energy Corporation owns and operates power infrastructure in the United States. The Company produces and sells electricity, capacity, and ancillary services in wholesale power markets in the United States, primarily in PJM and WECC, with its generation fleet principally located in the Mid-Atlantic region of the United States and Montana. The majority of its generation is produced at its zero-carbon nuclear and lower-carbon gas-fired facilities. Its generation capacity is 10,665 megawatts (MW). Its segments include PJM and Other. The PJM segment is engaged in electricity generation, marketing activities, commodity risk and fuel management within the PJM RTO or ISO markets and comprises Susquehanna and Talen’s natural gas and coal generation facilities. Its Other segment includes the operating and marketing activities of Talen Montana’s proportionate share of the Colstrip Units in the WECC market, the operating activities of Nautilus, and other development activities.


NDAQ:TLN - Post by User

Bullboard Posts
Post by Everswanon Mar 02, 2009 12:37pm
143 Views
Post# 15814106

Bear Value - TLN

Bear Value - TLN
I have completed my DD and I am holding my position until news day or until Mid-April.

Success is contingent to number of cycles.
4601 is not Asperin
Cytoxicity is high and impressive.
Delivery and selectivity have been proven.

It's now just a matter of how many patients are responsive to treatment.

Ras GDP and Rho inhibition are indicative of dual cascading down inhibition of multiple pathways all linked to GBM:

AKT PI3K pathway = apotheosis
Ras GDP Raf EKT pathway = cell proliferation
Cascapde 3 and 7 = apotheosis

The bears are now in full control of the market.

Bullboard Posts

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse